TXMD (TherapeuticsMD) Moat Score: 3/10 (As of Jul. 01, 2026)


TXMD TherapeuticsMD Inc TXMD
54 GF Score
Price $2.26
GF Value $2.06
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is TherapeuticsMD Moat Score?

TherapeuticsMD TXMD +5.12% 54 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates TXMD with a GF Score™ of 54/100 and a GF Value™ of $2.06 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, TherapeuticsMD ranks better than 86.13% on this metric.

TherapeuticsMD has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

TherapeuticsMD has No Moat: TherapeuticsMD Inc operates in the competitive pharmaceutical industry with limited differentiation. It lacks significant intellectual property, brand strength, or pricing power, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes TherapeuticsMD might have No Moat - Very weak/transient advantages.

TherapeuticsMD  (NAS:TXMD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

TherapeuticsMD Moat Score Related Terms

TXMD vs CPHI, RMTI, AYTU: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TherapeuticsMD Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Moat Score distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Moat Score falls into.


TXMD
54GF Score
TherapeuticsMD Inc TXMD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
TherapeuticsMD (TXMD) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, TherapeuticsMD ranks #143 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is TherapeuticsMD's Moat Score too high?
TherapeuticsMD's current Moat Score is 3. Based on the distribution chart, TherapeuticsMD ranks #143 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TherapeuticsMD has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TherapeuticsMD's Moat Score compare to CPHI and RMTI?
According to the Drug Manufacturers industry distribution chart, TherapeuticsMD ranks #143 out of 1031 companies for Moat Score. This places TherapeuticsMD in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. TherapeuticsMD's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TherapeuticsMD stock overvalued right now?
Based on GuruFocus' analysis, TherapeuticsMD (TXMD) is currently considered Fairly Valued. The stock's GF Value™ is $2.06, compared to a current price of $2.26 — trading 9.7% above its estimated fair value. The current Moat Score is 3. TherapeuticsMD's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For TherapeuticsMD (TXMD), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TherapeuticsMD (TXMD) Overvalued in 2026?

Based on GuruFocus' analysis, TherapeuticsMD stock appears to be overvalued. The current stock price of $2.26 is trading 9.7% above its estimated GF Value™ of $2.06. GuruFocus considers TherapeuticsMD to be Fairly Valued.

Key valuation signals for TXMD:

  • Moat Score: 3
  • GF Value™: $2.06 vs. price of $2.26 (9.7% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the TXMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TherapeuticsMD Business Description

Other Exchanges 29TA:Germany
Address 951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
54GF Score

Get the complete analysis for TXMD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.26
Price
$2.06
GF Value